Ultromics has secured a Category III Current Procedural Terminology (CPT) code from the American Medical Association (AMA) for its EchoGo Heart Failure system.
This development marks a significant step in improving the accessibility of this AI-driven technology in hospital outpatient settings.
Go deeper with GlobalData
The new CPT code, 0932T, will facilitate the adoption of EchoGo Heart Failure by streamlining the reimbursement process for healthcare providers.
Using AI, the platform can detect heart failure with preserved ejection fraction (HFpEF) from standard echocardiographic videos.
By analysing large datasets with advanced algorithms, the system can uncover patterns and correlations that may be missed by conventional diagnostic methods.
These AI insights assist clinicians in monitoring, diagnosing, and accelerating treatment decisions, thereby improving the detection and management of HFpEF.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe AMA’s new CPT code will become effective on 1 January 2025. It will replace the prior HCPCS outpatient code, C9786.
Additionally, EchoGo Heart Failure is covered in the hospital inpatient setting under the New Technology Add-on Payment (NTAP) code XXE2X19.
Category III CPT codes are temporary designations for emerging technologies and services.
The EchoGo Heart Failure already received 510(k) clearance from the US Food and Drug Administration (FDA) in December 2022.
A recent research published highlighted the performance of EchoGo Heart Failure in diagnosing HFpEF compared to existing clinical standards.
The system demonstrated high sensitivity and specificity, identifying 88% of HFpEF patients and 82% of non-HFpEF patients, surpassing routine clinical practice outcomes.
Ultromics CEO and founder Ross Upton said: “HFpEF represents a significant and growing patient population, accounting for 50% of heart failure cases worldwide, and may go undiagnosed in up to 64% of cases.
“We believe that EchoGo Heart Failure will transform diagnostic pathways for these patients, enable earlier intervention, improve quality of life, and deliver benefits to payors and healthcare systems.”
Earlier this year, Ultromics partnered with Pfizer to expedite the development and pursue FDA clearance for its AI platform to detect cardiac amyloidosis.
